Sympathetic Nervous System Modulation in Hypertension
Sympathetic Nervous System Modulation in Hypertension by Beta-adrenergic Blockade
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Essential hypertension with blood pressure less than 140/90 on either an ACE inhibitor or angiotensin receptor blocker
Exclusion Criteria:
- Known valvular heart disease of more than mild severity
- Known coronary artery disease defined by an angiographic coronary artery stenosis greater than or equal to 50% luminal diameter narrowing, acute or previous myocardial infarction, or previous coronary revascularization
- Known non-ischemic cardiomyopathy with left ventricular ejection fraction less than 50%
- Atrial fibrillation
- Current treatment with a β-adrenergic blocking drug or a calcium channel blocker
- Current treatment with a psychoactive or other drug known to alter 123I-MIBG uptake
- Participation in another research study within the prior 30 days
- A life-limiting disease process that is likely to preclude completion of study participation
- Pregnancy or breast feeding
- Inability or unwillingness to provide informed consent
- Baseline resting heart rate less than 65 beats per minute
- Diabetes
- Iodine allergy
- Unwilling to sign informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: metoprolol succinate
Subjects will undergo I-123 MIBG testing before and after sustained-release beta-adrenergic blockade.
|
Once daily, oral, 12.5 mg to 200 mg, dose titrated to reduce heart rate by 20% or to less than 65 beats per minute.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Improvement in Sympathetic Cardiac Innervation as Measured by I-123 MIBG Heart - Mediastinum Ratio
Time Frame: january 2018
|
24 subjects had baseline I-123 MIBG imaging.
No subject completed all aspects of the protocol.
The study was closed due to unfavorable publication related to metoprolol treatment for hypertension.
|
january 2018
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Myron C Gerson, M.D., University of Cincinnati
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Metoprolol
Other Study ID Numbers
Other Study ID Numbers
- #07-01-12-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.